These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28129003)

  • 1. Beyond platinum treatment for NSCLC: what does the future hold?
    Santarpia M; Karachaliou N; Rosell R
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):293-295. PubMed ID: 28129003
    [No Abstract]   [Full Text] [Related]  

  • 2. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles.
    Rossi A; Di Maio M
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):653-60. PubMed ID: 27010977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Best practice in the treatment of advanced squamous cell lung cancer.
    Ang YL; Tan HL; Soo RA
    Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
    Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
    Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of targeted agents monotherapy in advanced NSCLC.
    Zhang Q; Wu YL
    Expert Rev Clin Pharmacol; 2016; 9(1):143-55. PubMed ID: 26558941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
    Tanvetyanon T; Creelan BC; Antonia SJ
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of side effects with platinum doublet chemotherapy used for treatment of non-small cell lung cancer].
    Kudo K; Nakagawa K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():542-7. PubMed ID: 25831819
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout.
    Favoni RE; Alama A
    Drug Discov Today; 2013 Jan; 18(1-2):11-24. PubMed ID: 22885521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should anti-mesothelin therapies be explored in lung cancer?
    Thomas A
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):677-9. PubMed ID: 27210575
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted therapy of non-small-cell lung carcinoma.
    Tiwari D; Brodie SA; Brandes JC
    Ther Adv Respir Dis; 2012 Feb; 6(1):41-56. PubMed ID: 21730004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO; Ogunniyi A; Barbee MS; Drilon A
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
    Decatris MP; O'Byrne KJ
    Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy for advanced NSCLC: is platinum indispensable?].
    Pujol JL
    Rev Pneumol Clin; 2004 Jun; 60 Spec no 2():2S16-9. PubMed ID: 15211227
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers.
    Genova C; Rijavec E; Grossi F
    Expert Rev Anticancer Ther; 2016; 16(1):1-4. PubMed ID: 26567561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of second-line treatment options for non-small cell lung cancer.
    Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
    Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line?
    Gridelli C; Rossi A; Maione P; Ambrosio R; Barbato V; Bareschino MA; Schettino C; Palazzolo G; Sacco PC
    Clin Lung Cancer; 2010 Nov; 11(6):374-82. PubMed ID: 21062728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.